Clinical Trial Update: Study to Evaluate ctDNA of mCSPC Patients Receiving Apalutamide in Japan [Phase 4]

View source ↗

Summary

A Phase 4 trial update evaluating circulating tumor DNA in metastatic castration-sensitive prostate cancer patients in Japan treated with apalutamide.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-sensitive Prostate Cancer

Drugs mentioned

• Apalutamide (apalutamide)

Snippet

Sponsor: Kindai University | Conditions: Metastatic Castration-sensitive Prostate Cancer | Phase 4 | Status: UNKNOWN